CSV February 22, 2023 through February 22, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CALCIUM	IDENTIFICATIO	*USPNF Online*	Online	26-May-2023	1-Aug-2023	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ASCORBATE	N/*A.*							Characteristic emission lines for calcium at 184.0, 315.9, and 317.9 nm from the *Sample solution* correspond to those from the *Standard solution*, as obtained in the *Assay*. to: Characteristic emission lines for calcium at 184.0, 315.9, and 317.9 nm from the *Sample solution* correspond to those from the *Standard solution*, as obtained in the *Content of Calcium*.
METHYLPHENIDATE HYDROCHLORIDE EXS	ADDITIONAL REQUIREMENTS/*USP*	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	In USP Methylphenidate Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TENDED-RELEASE TABLETS	*Reference Standards* ?11?							Compound A RS: Change ?-Phenyl-2-piperidineacetic acid hydrochloride. to: (*RS*)-2-Phenyl-2-[(*RS*)-piperidin-2-yl]acetic acid hydrochloride.
PSEUDOEPHEDRINE HYDROCHLORIDE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	Change **Uniformity of Dosage Units ?905? Procedure for content uniformity** to: **Uniformity of Dosage Units ?905?:** Meets the requirements **Procedure for content uniformity,**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chewable tablets only AND In *Uniformity of Dosage Units*: Delete **Acceptance criteria**: Meet the requirements for chewable tablets
ACARBOSE TABLETS	IDENTIFICATION/*B.*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	Change The spectrum obtained from the *Sample solution* shows IR maxima in the regions of 3500–3200, 2950–2890, 1653–1633, and 1070–1000 cm^{-1}. to: The spectrum obtained from the sample preparation shows IR

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								maxima in the regions of 3500–3200, 2950–2890, 1653–1633, and 1070–1000 cm^{-1}.
POLYETHYLENE GLYCOL 1200 CETOSTEARYL ETHER	IDENTIFICATION	*USPNF Online*	Online	28-Apr-2023	1-Aug-2023	*NA*	*NA*	Change: **B. Test for Hydroxyl Group**: to: **B. Hydroxyl Value:** AND In *D./Analysis*: Change Dissolve or disperse the *Sample* in alcohol. to: Dissolve or disperse the *Sample* in 5 mL alcohol.
VIGABATRIN TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Analysis*: Change C_S = concentration of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ROSEMARY LEAF DRY AQUEOUS EXTRACT	COMPOSITION /*Content of Rosmarinic Acid*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	USP Vigabatrin Related Compound A in the *Standard solution* to: C_S = concentration of USP Vigabatrin Related Compound A RS in the *Standard solution* In *Standard solution B*: Change Before injection, pass through a membrane filter of 0.45-µL or finer pore size, to: Before injection, pass through a membrane filter of 0.45-µm or finer pore size, AND In *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BUPIVACAINE HYDROCHLORIDE INJECTION	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	Change Before injection, pass through a membrane filter of 0.45-µL or finer pore size, to: Before injection, pass through a membrane filter of 0.45-µm or finer pore size, In *Chromatographic system*/*Column*: Change 4-mm × 30-cm; packing L1 to: 3.9-mm × 30-cm; packing L1 AND In *System suitability*: Change [Note—The relative retention times for bupivacaine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride and dibutyl phthalate are about 1.0 and 1.2, respectively.] to: [Note—The relative retention times for bupivacaine and dibutyl phthalate are about 1.0 and 1.2, respectively.] AND In System suitability/Suitability requirements: Change **Resolution**: NLT 2.0 between bupivacaine hydrochloride and dibutyl phthalate **Relative standard deviation**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESCITALOPRAM TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	: NMT 1.0% for the ratio of bupivacaine to the internal standard from three replicate injections to: **Resolution**: NLT 2.0 between bupivacaine and dibutyl phthalate **Relative standard deviation**: NMT 1.0% for the peak response ratio of bupivacaine to the internal standard from three replicate injections In *Buffer*: Change Adjust with 1 N sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydroxide VS to a pH of 5.2. to: Adjust with 1 N sodium hydroxide to a pH of 5.2.
ROSEMARY	COMPOSITION /*Content of Phenolic Diterpenes*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Sample solution*: Change Before injection, pass through a membrane filter of 0.45-µL or finer pore size, to: Before injection, pass through a membrane filter of 0.45-µm or finer pore size,
BISOPROLOL FUMARATE	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	Change (±)-1-[[?-(2-Isop *p* -tolyl]oxy]-3-(iso propyl amino)-2 -propanol fumarate (2:1)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(salt) to: (±)-1-[[?-(2-Isop *p* -tolyl]oxy]-3-(iso propylamino)-2- propanol fumarate (2:1) (salt)
DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES	IDENTIFICATION	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	Change **A.** The UV-Vis spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*. to: **A.** The UV spectrum of the major peak of the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								corresponds to that of the *Standard solution*, as obtained in the *Assay*.
FLUVOXAMINE MALEATE TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Solution A*: Change 8 g/L of 1-pentanesulfonic acid sodium salt and 1 g/L of monobasic potassium phosphate in water. to: 8 g/L of 1-pentanesulfonic acid sodium salt and 1.1 g/L of monobasic potassium phosphate in water.
RISEDRONATE SODIUM DELAYED-RELEASE TABLETS	ASSAY	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	Delete [Note—Use a non-metallic liquid chromatography system for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								analysis.]
PINDOLOL	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Standard stock solution*: Change 1 mg/mL of USP Pindolol RS in *Mobile phase* prepared as follows. To a suitable amount of USP Pindolol RS add *Mobile phase* to fill about 90% of the total volume, and sonicate for about 5 min to dissolve. to: 1 mg/mL of USP Pindolol RS in *Mobile phase* prepared as follows. To a suitable amount of USP Pindolol RS add *Mobile phase* to fill about 90% of the total

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volume, and sonicate for about 5 min to dissolve. Dilute with *Mobile phase* to volume.
ESCITALOPRAM TABLETS	PERFORMANCE TESTS/ *Dissolution ?711?*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Test 1*/*Medium*: Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL AND In *Test 2*/*Medium*: Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL
POWDERED	COMPOSITION	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ROSEMARY	/*Content of Phenolic Diterpenes*							*solution*: Change Before injection, pass through a membrane filter of 0.45-µL or finer pore size, to: Before injection, pass through a membrane filter of 0.45-µm or finer pore size,
ISOFLURANE	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Analysis*: Change Result = $(r_U/r_S) \times C_S \times (1/F)$ to: Result = $(r_U/r_S) \times C_F \times (1/F)$ AND Change C_S = final concentration of USP Isoflurane Related Compound B RS in the *Standard solution* (%) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUTICASONE PROPIONATE NASAL SPRAY	OTHER COMPONENTS/*Content of Phenylethyl Alcohol*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	C_F = final concentration of USP Isoflurane Related Compound B RS in the *Standard solution* (%) In *Sample solution*: Change Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40 mL of *Diluent*, and sonicate for 10 min until the supernatant is clear. Use the clear supernatant for analysis. to: Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Add about 40 mL of *Diluent*, and sonicate for 10 min. Dilute with *Diluent* to volume, and shake. Allow to stand for 10 min until the supernatant is clear. Use the clear supernatant for analysis.
THYROID TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Chromatographic system*: Change **Column:** 4.6-cm × 25-cm; packing L1 to: **Column:** 4.6-mm × 25-cm; packing L1
PRAZOSIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Test 2/Analysis*: Change C_S =

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	?711?							concentration of USP Prazosin Hydrochloride RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Prazosin Hydrochloride RS in the *Standard solution* (mg/mL) AND Change M_{r2} = molecular weight of prazosin hydrochloride, 419.86 to: M_{r2} = molecular weight of prazosin hydrochloride, 419.87
ORPHENADRINE CITRATE, ASPIRIN, AND	ADDITIONAL REQUIREMENTS/*USP*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change USP 2-Methylbenzhydrol RS

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAFFEINE TABLETS	*Reference Standards* ?11?							to: USP Methylbenzhydrol RS
ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION	*Assay*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed in the *Assay* under *Erythromycin Ethylsuccinate Oral Suspension*. to: Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed for erythromycin under *Antibiotics—Micr*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								obial Assays ?81?, using an accurately measured volume of the reconstituted suspension, freshly mixed and free from air bubbles, blended for 4 ± 1 minutes in a high-speed glass blender jar with sufficient methanol to give a stock solution containing the equivalent of about 1 mg of erythromycin per mL. Dilute this stock solution quantitatively with *Buffer B.3* to obtain a *Test Dilution* having a concentration

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								assumed to be equal to the median dose level of the Standard.
DEXTRATES	ASSAY/ *Dextrose Equivalent*	*USPNF Online*	Online	31-Mar-2023	1-May-2023	*NA*	*NA*	In *Analysis*: Change r_A = peak response of each saccharide degree of polymerization (DP_1–DP_3) in the *Sample solution* (If any peaks of DP_4 and above are observed in the sample, take the summation of all peak responses DP_{4+} and use this value as r_U.) to: r_A = peak response of each saccharide degree of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								polymerization (DP_1–DP_3) in the *Sample solution* (If any peaks of DP_4 and above are observed in the sample, take the summation of all peak responses DP_{4+} and use this value as r_A.)
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Test 2*/*Analysis*: Change C_S = concentration of USP Norethindrone Acetate RS (mg/mL) or USP Ethinyl Estradiol RS (ug/mL) in the *Standard solution* to: C_S = concentration of USP Norethindrone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Acetate RS (mg/mL) or USP Ethinyl Estradiol RS (µg/mL) in the *Standard solution*
ERYTHROMYCIN DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Test 1*: Change **Buffer stage Medium**: 0.05 M pH 6.8 phosphate buffer (see *Reagents, Indicators, and Solutions—Buffer Solutions*) to: **Buffer stage Medium**: 0.05 M pH 6.8 phosphate buffer (see *Reagents, Indicators, and Solutions—Buffer Solutions*); 900 mL
CELL BANKING	5. CELL BANK CHARACTERIZ	*USPNF Online*	Online	31-Mar-2023	1-May-2023	*NA*	*NA*	In *Table 4*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PRACTICES FOR RECOMBINANT BIOLOGICS	ATION							In vitro assay[d,e] + + +[f] to: In vitro assay[d,e] + ?[f] +
CALCIUM LACTATE	CHEMICAL INFORMATION	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change Calcium lactate (1:2) hydrate to: Calcium lactate hydrate AND Change Calcium lactate (1:2) pentahydrate to: Calcium lactate pentahydrate
THYROID	ASSAY/ *Procedure*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Chromatographic system*: Change **Column**: 4.6-cm × 25-cm; packing L1 to: **Column**: 4.6-mm × 25-cm; packing

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PRAZOSIN HYDROCHLORIDE CAPSULES	ASSAY/ *Procedure*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	L1 In *Analysis*: Change C_S = concentration of USP Prazosin Hydrochloride RS in the *Standard solution* (µg/mL) C_U = nominal concentration of prazosin in the *Sample solution* (µg/mL) M_{r1} = molecular weight of prazosin, 383.41 M_{r2} = molecular weight of prazosin hydrochloride, 419.86 to: C_S = concentration of USP Prazosin Hydrochloride RS in the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution (mg/mL) C_U = nominal concentration of prazosin in the *Sample solution* (mg/mL) M_{r1} = molecular weight of prazosin, 383.41 M_{r2} = molecular weight of prazosin hydrochloride, 419.87
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE TABLETS	IM PURITIES/*Limit of 2-Methylbenzhydrol*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Standard solution*: Change 7.5 µg/mL of USP 2-Methylbenzhydrol RS in methanol to: 7.5 µg/mL of USP Methylbenzhydrol RS in methanol AND In *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION	*Identification*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	C_S = concentration of USP 2-Methylbenzhydrol RS in the *Standard solution* (mg/mL) to: C_S = concentration of USP Methylbenzhydrol RS in the *Standard solution* (mg/mL) Change Proceed as directed in the *Identification* test under *Erythromycin Ethylsuccinate Oral Suspension*, beginning with “Prepare a Standard solution.” to: Prepare a Standard

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution of USP Erythromycin Ethylsuccinate RS in methanol containing about 3 mg per mL. Apply separately 10 µL each of the test solution and the Standard solution to a suitable thin-layer chromatographic plate (see *Chromatography* ?621?) coated with a 0.25-mm layer of chromatographic silica gel mixture, and allow to dry. Place the plate in an unlined chromatographic chamber, and develop the chromatograms in a solvent

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								system consisting of a mixture of methanol and chloroform (85:15) until the solvent front has moved about 9 cm. Remove the plate from the chamber, mark the solvent front, and allow the solvent to evaporate. Spray the plate with a mixture of dehydrated alcohol, *p* -methoxybenzal dehyde, and sulfuric acid (90:5:5). Heat the plate at 100° for 10 minutes, and examine the chromatograms, in which the erythromycin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and succinic acid moieties appear as black-to-purple spots: the R_F values of the principal spots obtained from the test solution correspond to those obtained from the Standard solution.
LOW MOLECULAR WEIGHT HEPARIN MOLECULAR WEIGHT DETERMINATIONS	PROCEDURE	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In footnote 1 in *Molecular Weight Measurements of Low Molecular Weight Heparins by Gel Permeation Chrom atogr aphy/ Chromatographic system/ Colum ns/Analytical*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVORPHANOL TARTRATE TABLETS	PERFORMANCE TESTS/ *Uniformity of Dosage Units* ?905?	*USPNF Online*	Online	31-Mar-2023	1-Aug-2023	*NA*	*NA*	Change guard column TSK SWXL 6-mm × 4-mm; to: guard column TSK SWXL 6-mm × 4-cm; In *Sample solution*: Change Nominally about 80 ug/mL of levorphanol tartrate in *Diluent* prepared as follows. to: Nominally about 80 µg/mL of levorphanol tartrate in *Diluent* prepared as follows.
GLYCYL-L-TYROSINE	IMPURITIES/*Related Compounds*	*USPNF Online*	Online	24-Feb-2023	1-Jun-2023	*NA*	*NA*	In *Buffer solution*: Change Dissolve 6.84 g of potassium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phosphate in 1000 mL of water. to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of water.
MIRTAZAPINE TABLETS	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	In *System suitability/Suitability requirements/Resolution*: Change 10-ketomirtazpine to: 10-ketomirtazapine AND In *Table 1*: Change 1-Ketomirtazpine[c] to: 1-Ketomirtazapine[c]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
METAPROTERENOL SULFATE ORAL SOLUTION	*Identification*/*A.*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed as directed in *Identification* test *A* under *Metaproterenol Sulfate Inhalation Solution*, beginning with “Allow the spots to dry”: to: Allow the spots to dry, and develop the chromatogram in a solvent system consisting of the upper layer of a freshly prepared mixture of butyl alcohol, water, and formic acid (50:25:7) until the solvent front has moved about three-fourths of the length of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate. Locate the spots on the plate by examination under short-wavelength UV light:
SOTALOL HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	In *Analysis*: Change Calculate the percentage of any unspecified impurities in the portion of Sotalol Hydrochloride taken: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ r_U= sum of all the peak responses of all unspecified

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								impurities from the *Sample solution* to: Calculate the percentage of any unspecified impurity in the portion of Sotalol Hydrochloride taken: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ r_U = peak response of each unspecified impurity from the *Sample solution* AND In *Table 1*: Change Any unspecified impurities to: Any unspecified impurity
LIDOCAINE HYDROCHLORID	*Assay for lidocaine*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed with

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E AND DEXTROSE INJECTION	*hydrochloride*							Injection as directed in the *Assay for lidocaine hydrochloride* under *Lidocaine and Epinephrine Injection*. to: Proceed with Injection as directed in the *Assay for lidocaine hydrochloride* under *Lidocaine Hydrochloride and Epinephrine Injection.*
TRIETHYL CITRATE	ASSAY/ *Procedure*	*USPNF Online*	Online	24-Feb-2023	1-May-2023	*NA*	*NA*	In *System suitability*/*Suitability requirements*/*Tailing factor*: Change NMT 1.5 for the triethyl citrate to trimethyl citrate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peaks to: NMT 1.5 for the triethyl citrate and trimethyl citrate peaks
METAPROTERENOL SULFATE TABLETS	*Identification*/*A.*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed as directed in *Identification* test *A* under *Metaproterenol Sulfate Inhalation Solution*, beginning with “Allow the spots to dry”: to: Allow the spots to dry, and develop the chromatogram in a solvent system consisting of the upper layer of a freshly prepared mixture of butyl alcohol, water, and formic acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(50:25:7) until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate. Locate the spots on the plate by examination under short-wavelength UV light:
MESO-ZEAXANTHIN	IDENTIFICATION/*C*.	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin
CHLOROPROCAINE HYDROCHLORIDE	ASSAY/ *Procedure*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Sample solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION								Transfer about 100 mg of chloroprocaine hydrochloride to a 100-mL volumetric flask, dissolve in 40 mL of methanol, and dilute with water to volume. to: Transfer a volume of Injection, equivalent to about 100 mg of chloroprocaine hydrochloride to a 100-mL volumetric flask, add 40 mL of methanol, and dilute with water to volume.
POLYETHYLENE GLYCOL STANDARDS WITH MOLECULAR WEIGHTS OF	CHEMICAL INFORMATION	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change CAS RN®: 25332-68-3. to: CAS RN®: 25322-68-3.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
1000, 2000, 3000, 4000, AND 6000 DALTONS (G/MOL)								
DEXAMETHASONE SODIUM PHOSPHATE INJECTION	ASSAY/ *Procedure*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r22}) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$
MESO-ZEAXANTHIN PREPARATION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In USP *meso* -Zeaxanthin RS: Change (3*R*,3?*S*-*meso*)-Zeaxanthin. to: (3*R*,3?*S*)-Zeaxanthin.
AZTEC MARIGOLD ZEAXANTHIN EXTRACT	IDENTIFICATION/*C*.	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change (3*R*,3?*S* *meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEAD	REQUIREMENTS FOR PROCEDURE VALIDATION	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	Change • **Precision Repeatability** to: • **Precision**
METARAMINOL BITARTRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards ?11?*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In USP Metaraminol Enantiomer RS: Change 3-[(1*S*,2*R*)-2-Amino-1-hydroxypropyl]phenol. $C_9H_{13}NO_2$ 167.21 to: 3-[(1*S*,2*R*)-2-Amino-1-hydroxypropyl]phenol D-tartrate. $C_9H_{13}NO_2$? $C_4H_6O_6$ 317.29
MESO-ZEAXANTHIN PREPARATION	IDENTIFICATION/*C*.	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	Change (3*R*,3?*S*-*meso*)-zeaxanthin to: (3*R*,3?*S*)-zeaxanthin

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »